World Markets
MRK

Sanofi's paediatric hexavalent vaccine approved by U.S. FDA

Reuters

PARIS, Dec 26 () - The U.S. Food and Drug Administration approved Sanofi's new paediatric vaccine immunizing children against six diseases, the French pharmaceutical lab said on Wednesday.

Sanofi developed the new vaccine, dubbed Vaxelis, in partnership with Merck.

Vaxelis is designed for children aged 6 weeks to 4 years old and is designed to keep them from contracting diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to haemophilus influenzae type B.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MRK

Other Topics

Stocks Economy

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More